Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0KCJRP
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
nAPC-ADC
|
|||||
| Synonyms |
NAPC-ADC
Click to Show/Hide
|
|||||
| Organization |
Peking University.;Changping Laboratory.
|
|||||
| Drug Status |
Investigative
|
|||||
| Drug-to-Antibody Ratio |
4
|
|||||
| Structure |
|
|||||
| Antibody Name |
sibrotuzumab
|
Antibody Info | ||||
| Antigen Name |
Prolyl endopeptidase FAP (FAP)
|
Antigen Info | ||||
| Payload Name |
Monomethyl auristatin E
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
MC-Radiation-responsive linker
|
Linker Info | ||||
| Conjugate Type |
Random conjugation through reduced inter-chain cysteines.
|
|||||
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) | 575.8 nM | High FAP expression (+++) | ||
| Method Description |
the half-maximal inhibitory concentration (IC50) of NAPC-ADC against 4T1-FAP cells
|
||||
| In Vitro Model | Malignant neoplasms of the mouse mammary gland | 4T1-FAP cells | CVCL_0125 | ||